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Introduction
There is a need for an improved classification system for
epithelial proliferative lesions and in situ malignancy of
the breast, as reproducibility of diagnosis and categori-
sation is problematic. Clearly, classification of any
disease process should have biological and clinical rele-
vance as well as high reproducibility. As with diseases
elsewhere in the body, distinguishing hyperplasia from
neoplasia in the breast is based on identification of a
clonal cell process. Clonality is recognised by uniformity
of morphology and phenotype, and markers such as
cytokeratin expression or hormone receptor expression
can be used. While usual epithelial hyperplasia is mor-
phologically and phenotypically heterogeneous, atypical
ductal hyperplasia (ADH) and established ductal carci-
noma in situ (DCIS) are homogeneous in cell type and
marker expression. In addition, studies of loss of het-
erozygosity in low-grade DCIS and ADH have revealed
similar genetic changes in the two conditions [1]; this
finding is interpreted as confirmatory evidence that
these are clonal processes and both therefore fulfil the
basic concept of neoplasia. The frequency of loss of
heterozygosity in cases of usual hyperplasia is much
lower.
The conceptual distinction between benign neoplasia and
in situ malignancy in the intraductal epithelial proliferations
of the breast has been arbitrarily drawn at the boundary
between ADH and low-grade DCIS. This may not be the
appropriate place. Indeed morphological, immunohisto-
chemical, and genetic studies indicate that it is more
appropriate to draw the boundary between usual epithelial
hyperplasia and ADH [2]. Nevertheless, this three-tier
system is the system accepted and used clinically at
present and is outlined below.
Atypical ductal hyperplasia
The distinction between DCIS and ADH is based on evi-
dence derived from many series, including studies by
David Page and co-workers [3]. These have been sup-
ported by other studies, such as the Nurses’ Health Study
[4,5]. Clearly, ADH is a rare condition [6], being seen in
4% of symptomatic benign biopsies [7], although it is
more common in association with screen-detected benign
microcalcifications (31%) and is seen most commonly as
an incidental finding [7].
The significance of the diagnosis of ADH lies in the
increased risk of invasive breast carcinoma, which is about
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four to five times that of the general population [8–12] and
may be even greater for premenopausal women
(approaching a sixfold risk) [12]. This risk is further
increased if the patient has a first-degree relative with
breast cancer (10-fold risk) [8,13,14].
The diagnostic criteria used to define ADH are imperfect.
ADH was described initially based on exclusion rather than
positive criteria, i.e. the recognition of some but not all of
the features of DCIS (as well as the lack of the characteris-
tics of usual-type epithelial hyperplasia) [8]. This definition
of ADH has been updated and, while the diagnosis stills
rests on an absence of all the features of DCIS, additional
supporting features have been described [15,16]. The view
of Page and colleagues that the cellular changes of DCIS
are present but occupy fewer than two separate duct
spaces is widely accepted. Others use a 2-mm cutoff; a
lesion less than 2mm in maximum dimension being classi-
fied as ADH and a larger one as DCIS [17]. These criteria
recognise essentially the same lesions. In essence, ADH is
usually small and focal, measuring less than 2 to 3mm.
Larger foci are accepted if associated with a radial
scar/complex sclerosing lesion or a papilloma.
There are three components to the diagnosis of ADH,
namely the architectural pattern, cytology, and disease
extent. ADH is formed from a uniform population of small or
medium-sized, round, cuboidal or polygonal hyperchromatic
cells, which are regularly arranged. The nuclei are evenly dis-
tributed and may form a rosette-like pattern. Single small
nucleoli only are present. Mitoses, particularly abnormal
forms, are infrequently seen. Geometric spaces are present
and, in the cribriform type, the cells are arranged at right
angles to the bridges formed. Micropapillary ADH is also
recognised and a solid pattern may very rarely be seen.
Small foci of necrosis may rarely be identified in ADH and do
not indicate that the process should be classified as DCIS.
At present, it is recommended that the diagnosis of ADH
should be restricted to lesions that show the features
described by Page and colleagues [8,15], to which the
quantified risk of developing breast carcinoma is linked.
Even then, the diagnosis of ADH should be made with
caution and only if low-grade DCIS has been seriously
considered in the differential diagnosis. Lesser changes
for which the possible classification lies between florid
usual epithelial hyperplasia and ADH are less relevant with
regard to a risk of developing breast carcinoma and
should not be classified as ADH. However, it should also
always be borne in mind that a proliferation at the edge of
a biopsy may represent the periphery of a more estab-
lished lesion of DCIS and further excision of the adjacent
tissue may be warranted.
The major problem of ADH is the difficulty in achieving
acceptable levels of concordance or consistency in diagno-
sis. Various strategies have been used to try to improve its
recognition, including revision of the criteria, providing a
more positive basis for recognition, and education and
emphasis on the use of one system by all for diagnosis [15].
Despite the adoption of such principles, the reliable classifi-
cation around the boundaries of ADH and the ‘borderline’
epithelial intraductal proliferations in the breast remained
elusive in several [18,19], although not all [20], studies.
Ductal carcinoma in situ
DCIS is defined as a proliferation of malignant epithelial
cells within the breast parenchymal structures with no evi-
dence of invasion across the basement membrane. This
lack of invasive foci may be confirmed with immunohisto-
chemical assessment for the presence of myoepithelial
cells (e.g. smooth muscle actin, smooth muscle myosin) or
basement membrane (collagen type IV, laminin). Pure
DCIS accounts for 15 to 20% of breast cancers com-
pared with only 5% of cases before the advent of breast
cancer screening [21–23].
DCIS is a unicentric disease process, as shown by elegant
three-dimensional studies showing that only one region of
the breast is involved in the vast majority of cases and two-
thirds of tumours involve only one quadrant [24]. However,
the natural history of DCIS is not well understood, as it has
largely been extrapolated from historical series and
reassessment of previously misdiagnosed lesions, most of
which were low grade. The numbers in these series are
low; in the series of Page and colleagues [25,26],
28 patients were found to have DCIS from the 11,760
biopsies reviewed, and none of these lesions was of the
comedo type. Studies suggest that up to 50% of patients
with microscopic foci of DCIS develop invasive carcinoma.
The invasive lesion occurs in the same area as the original
lesion [27,25], indicating a precursor process. Series of
cases in which DCIS was not completely excised have also
been reviewed [28], and these indicate that progression to
invasion is related to the subtype of DCIS: comedo disease
progresses into invasive carcinoma both more often and
more rapidly than low-grade DCIS.
Several systems for subdividing DCIS have been
described. The traditional classification based on a combi-
nation of architectural growth pattern and cytological fea-
tures provides poor reproducibility, with up to 30% of
cases in multicentre trials requiring reclassification [29].
The National Coordinating Group for Breast Screening
Pathology in the United Kingdom [16] recommend a
system derived from the work of Holland and colleagues
[30], classifying DCIS as high, low, or intermediate grade
based on cytonuclear features.
High-nuclear-grade DCIS is composed of pleomorphic
large cells with abundant, including abnormal, mitoses.
Architecture is variable, although often solid. Central256
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necrotic debris may undergo calcification. Low-nuclear-
grade DCIS is composed of uniform cells, which are small.
The nuclei are also small, although larger than in adjacent
normal epithelium. Low-nuclear-grade DCIS frequently has
a cribriform or micropapillary configuration; often both pat-
terns are seen in the same lesion. Individual apoptotic
cells or small foci of necrosis may be seen and associated
calcification may be present, usually within inspissated
secretions. Intermediate-grade disease is diagnosed if the
neoplastic nuclei show pleomorphism of a degree
between high- and low-grade DCIS. The nuclear-to-cyto-
plasmic ratio is often high in intermediate disease. The
growth pattern may be micropapillary or cribriform but is
often solid. Some degree of polarisation around architec-
tural features may be seen.
This system of classification has clinical relevance and
shows reasonable reproducibility [31]. Several other
systems for typing of DCIS have been proposed, including
categorisation based on nuclear grade and necrosis
[32,33]. Silverstein and colleagues [32] have grouped
DCIS into high-grade, non-high-grade with necrosis, and
non-high-grade without necrosis and found an association
between the subtypes and local recurrence and disease-
free survival [34].
Conclusion
The existing system for the classification of intraductal
epithelial proliferations assumes a spectrum from usual
epithelial hyperplasia through ADH and low-grade DCIS to
high-grade disease. Recently published work using com-
parative genomic hybridisation to investigate DCIS of the
breast has prompted the proposal of a hypothetical model
for the pathogenesis of DCIS, which recognises genetic
lesions associated with particular morphological subtypes.
These data also indicate that ADH/low-grade DCIS is
more closely related to lobular in situ neoplasia than to
high-grade DCIS. Thus new molecular genetic techniques
are demonstrating that current dogma is untrue: (a) the
fundamental separation of LCIS from DCIS may not be
appropriate; (b) distinguishing ADH from low-grade DCIS
is illogical; (c) the assumption that DCIS is a spectrum of
the same disease is flawed. It is likely that some of these
new methods will form the basis of a revised system of
classification in the future with an underlying molecular
genetic basis while maintaining clinical relevance.
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